BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 2 days ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 2 days ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 2 days ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 2 days ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 2 days ago Abbott reports positive results from study on its atrial fibrillation therapies 2 days ago Atmus Welcomes Heath Sharp to Board of Directors 2 days ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 2 days ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 4 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 4 days ago
ADVERTISEMENT
Market News

Abbott Laboratories achieves double-digit earnings growth

Abbott (NYSE: ABT), we’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that […]

January 22, 2026 1 min read

Abbott (NYSE: ABT), we’re driven by a shared mission: to help you live a healthier, fuller life. The revolutionary health technologies and products we create serve that very human purpose. Managing diabetes. Monitoring hearts. Easing chronic pain. Through our products, our science and our partnerships, we work to bring better health to more people, so that our next breakthrough can lead to theirs.

Current Stock Price:

  • $120.73

Market Capitalization:

  • $209.9 billion
  • Enterprise Value (EV): $215.2 billion

Valuation:

  • Trailing P/E: 15.2
  • Forward P/E: 21.8
  • Indicates ABT’s earnings relative to its price are moderate compared with many large healthcare peers.
  • Growth-Adjusted Valuation
    • PEG Ratio: 2.26 (higher number suggests slower expected growth relative to current valuation).
  • Sales & Cash Flow Multiples
    • P/S (Price/Sales): ~4.8
    • P/B (Price/Book): ~4.1
    • P/FCF (Price/Free Cash Flow): ~30.4
    • EV/EBITDA: ~18.3

ADVERTISEMENT